| Cover | 1 |
|---|
| Contents | 6 |
|---|
| Prognostic Factors in Histopathology ofLung Cancer | 8 |
|---|
| Abstract | 8 |
| Tumor Size: An Essential Prognostic Factor in Lung Cancer | 10 |
| Small Cell Lung Cancer | 10 |
| Prognosis and Predictive Factors in Small Cell Lung Cancer | 11 |
| Histological Subtype: A Prognostic Factor in NSCLC | 12 |
| Squamous Cell Carcinoma Histological Subtypes Associated with Poor Prognosis | 12 |
| Adenocarcinoma Histological Subtypes Associated with Poor Prognosis | 13 |
| Bronchioloalveolar Cell Carcinoma Growth Pattern: A Favorable Prognostic Factor | 13 |
| Large Cell Carcinomas | 14 |
| Prognostic Implication of Molecular Markers | 15 |
| Conclusion | 19 |
| References | 20 |
| FDG-PET/CT in Lung Cancer: An Update | 22 |
|---|
| Abstract | 22 |
| Non-Small Cell Lung Cancer | 23 |
| Staging of Lung Cancer – Distant Metastases | 32 |
| Prediction and Monitoring Response to Therapy | 40 |
| Pleural Metastases | 42 |
| Cost-Effectiveness | 43 |
| Small Cell Lung Cancer | 44 |
| References | 44 |
| Whole-Body Magnetic Resonance Imaging for Staging of Lung Cancer | 53 |
|---|
| Abstract | 53 |
| Technical Aspects of Whole-Body MRI | 54 |
| Staging of Lung Cancer Using Whole-Body MRI | 54 |
| Conclusions | 60 |
| References | 60 |
| Bronchoscopy/Endobronchial Ultrasound | 62 |
|---|
| Abstract | 62 |
| EBUS-TBNA: Technique | 63 |
| Clinical Results | 65 |
| Complications | 67 |
| Conclusion | 67 |
| References | 68 |
| New Developments in Videomediastinoscopy: Video-Assisted Mediastinoscopic Lymphadenectomy and Mediastinoscopic Ultrasound | 70 |
|---|
| Abstract | 70 |
| Methods | 71 |
| Results | 71 |
| Comments | 74 |
| Implications for Clinical Practice and Further Research | 76 |
| References | 77 |
| Resection in Stage I/II Non-Small Cell Lung Cancer | 78 |
|---|
| Abstract | 78 |
| Surgery in Stages I and II | 79 |
| Conclusion | 82 |
| References | 82 |
| Role of Mediastinal Lymph Node Dissection in Non-Small Cell Lung Cancer | 85 |
|---|
| Abstract | 85 |
| Surgical Technique of Systematic Lymph Node Dissection | 86 |
| Role of Nodal Involvement on Survival | 88 |
| Impact of Mediastinal Lymph Node Dissection on Operative Morbidity, Mortality and Quality of Life | 88 |
| Diagnostic Role of Mediastinal Lymph Node Dissection | 89 |
| Therapeutic Role of Mediastinal Lymph Node Dissection | 90 |
| Conclusion | 91 |
| References | 91 |
| Radiation Therapy for Early Stage (I/II) Non-Small Cell Lung Cancer | 94 |
|---|
| Abstract | 94 |
| Radiation Therapy alone in Early Non-Small Cell Lung Cancer | 95 |
| Avenues for an Improvement of RT Alone in Early NSCLC | 98 |
| References | 99 |
| Stereotactic Body Radiation Therapy for Early Non-Small Cell Lung Cancer | 101 |
|---|
| Abstract | 101 |
| Definitions of Stereotactic Body Radiation Therapy | 102 |
| Staging Procedures before SBRT | 104 |
| Implementation of Techniques in Clinical Routine | 105 |
| Biological Basis of Hypofractionated SBRT | 108 |
| Historical Aspects and Early Clinical Experience in SBRT of Lung Cancer | 109 |
| Clinical Experience | 109 |
| Follow-Up Recommendations | 116 |
| Future | 117 |
| References | 117 |
| Extended Surgical Resection in Stage III Non-Small Cell Lung Cancer | 122 |
|---|
| Abstract | 122 |
| Discussion of Stage-Related Treatment | 123 |
| Conclusions | 127 |
| References | 127 |
| Stage III: Definitive Chemoradiotherapy | 129 |
|---|
| Abstract | 129 |
| Optimization of Combined Radiotherapy and Chemotherapy | 130 |
| Which Chemotherapy and Radiotherapy Regimens Are Optimal for
|
